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Background. Although cardiac hemangiomas, as rare benign cardiac tumors, have been described in previous case reports, the role
of radiation therapy in an unresectable cardiac hemangioma in adult has not been reported. We present a case report of a rare
unresectable cardiac cavernous hemangioma treated with radiotherapy. Case Presentation. A 45-year-old female with new onset
of coughing and worsening shortness of breath was found to have a biopsy proven cardiac cavernous hemangioma. Surgery
was aborted due to excessive bleeding, and she was then treated with radiotherapy. A total dose of 30 Gy in 15 fractions was
given using intensity-modulated radiation therapy (IMRT) to the mass with a modiﬁed 1 cm margin. Complete clinical
symptomatic relief was achieved with reduction of the mass posttreatment. Ten-year follow-up revealed a stable, reduced
hemangioma with no recurrence of symptoms. Conclusions. This is a rare example of cardiac hemangioma that developed in
the right ventricle and compressed several major vessels. Radiotherapy may be safely used for treatment of unresectable cardiac
hemangioma.

1. Introduction

2. Case Presentation

Cardiac hemangiomas are extremely rare primary cardiac
tumors, with a reported incidence of <2% among all primary
heart tumors [1]. They can occur at any age and appear anywhere within the heart, with patients presenting with various
clinical symptoms. Radiation therapy has been historically
used to treat a broad variety of benign disorders. More clinical indications for radiotherapy at diﬀerent anatomic sites
including heart and peripheral vascular system have been
identiﬁed and included according to international, up-todate surveys [2]. However, treatment with radiation therapy
has not been reported in any published cases for cardiac
hemangioma in adults. Therefore, we report a rare case of
surgically unresectable cardiac hemangioma that was treated
successfully with radiation therapy. Ten years of follow-up
has continued to show signiﬁcantly reduced size followed
by stability of the mass and no recurrence of clinical symptoms as of the last follow-up in 2021.

A 45-year-old female with years of excessive tiredness presented with coughing and worsening shortness of breath.
Marked cardiomegaly with probable pericardial eﬀusion
was found on chest X-ray. This was followed by a CT angiogram of the chest, which showed an ill-deﬁned mass extending from the pericardial surface anteriorly and pressing upon
or involving the right ventricular free wall with moderate-tolarge amount of pericardial eﬀusion. A subsequent cardiac
MRI showed a partly mobile intrapericardial mass anterior
to the right atrium (RA) and right ventricle (RV) measuring
8:6 × 13:5 cm in size (Figure 1). Encasement of the main pulmonary artery and right coronary artery with partial encasement of ascending aorta, right superior pulmonary veins,
and superior vena cava (SVC) was also noted. There was
no gross invasion into these vessels. This was initially diagnosed as a liposarcoma, and cardiothoracic surgery was consulted for resection. Intraoperatively, the tumor was deemed
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Figure 1: Magnetic resonance imaging at our institution revealed a lesion measuring 8:6 × 13:5 cm.

to be unresectable as it was invading into the wall of the RV,
and there was excessive bleeding. However, a biopsy was
obtained and reported as a cavernous hemangioma. At this
point, radiation oncology was consulted, and the decision
was made to oﬀer her external beam radiation therapy
(EBRT). She received a course of 30 Gy in 15 fractions using
intensity-modulated radiation therapy (IMRT) to the mass
with a modiﬁed 1 cm margin in May of 2009. IMRT was
chosen to allow precise radiation dose to the target and
reduce dose to surrounding organs at risk (OAR) such as
the heart, lungs, and esophagus. Patient was treated successfully with 6-MV photons delivered using a Varian Linear
Accelerator (Varian Medical Systems Inc., Palo Alto, CA).
The mean heart dose was 17.2 Gy, and the volume of the
lung receiving 20 Gy was 5% (Figures 2(a) and 2(b)). This
plan met (modiﬁed) quantitative analysis of normal tissue
eﬀects in the clinic (QUANTEC) dose constraints for both
heart and lungs; mean heart dose is less than 26 Gy and
bilateral lungs V20 less than 30% [3, 4]. A repeat cardiac
MRI (Figure 3) a year after treatment showed a signiﬁcant
decrease in the size of the tumor and no reaccumulation of
pericardial ﬂuid. The patient was followed on a regular basis
by the cardiologist and subsequently underwent regular cardiac MRIs over many years showing stable mass size without
pericardial eﬀusion; no symptom recurrence was ever noted.
Patient was last seen by cardiology in 2021 and was doing
well with no current complaints. The most up-to-date MRI
as of June 2022 was read as continued decrease in size in
the mass upon comparison to prior imaging (Figure 4).

3. Discussion
Cardiac hemangiomas are extremely rare primary cardiac
tumors, with a reported incidence of <2% among all primary
heart tumors [1]. They are benign vascular tumors composed of cavernous vascular channels or capillaries [5]. A
capillary hemangioma is the most common type of hemangioma, and it is made of small capillaries that are normal

in size and diameter. In contrast to a capillary hemangioma,
a cavernous hemangioma in the heart is less common and is
made up of multiple thin- and/or thick-walled vessels that
are dilated. In our case, the tumor was a cavernous hemangioma. Most aﬀected patients are asymptomatic, and majority of reported cases were identiﬁed while working up the
symptoms. Among nonspeciﬁc symptoms, the most common one is exertional dyspnea [6–8]. In these studies, there
is usually a variety of clinical presentations in patients
depending on multiple factors including size and location.
Our patient had a long history of shortness of breath, and
she presented with acute onset of coughing and worsening
shortness of breath.
Cardiac hemangiomas can arise anywhere and appear at
any size in the heart. However, hemangiomas of the right
ventricle with encasement of major vessels are extremely
rare [7]. Among the 172 cases of cardiac hemangioma
reviewed by Li et al., size varied from 0.5 to 14 cm with an
average size of 4.48 cm. In this reported case, the size was
measured to be 13.5 cm in greatest dimension. Only 7.6%
exceeded 10 cm according to Li et al. Cardiac hemangiomas
are usually misdiagnosed as other cardiac neoplasms. This is
evidenced by the fact that more than 65% of cases, of a set of
44 reported, were misdiagnosed preoperatively [7]. It was
not until proven by biopsy that the lesion in our patient
was conﬁrmed to be a cardiac cavernous hemangioma.
Surgical excision is the recommended ﬁrst-line therapy
in all symptomatic patients with cardiac tumors based on
the low incidence of postoperative long-term adverse events
and recurrence [9]. Partial tumor resection is equally as
eﬀective as complete removal [7]. Conservative treatment
such as corticosteroid and radiotherapy for cardiac hemangioma was only reported in very few cases. Only one infantile case of an unresectable pericardial hemangioma treated
with radiotherapy was reported by Yoshikawa et al. The
pericardial hemangioma was resolved successfully in 2
months with delivery of 2,050 rad [10]. For treatment of
unresectable large hemangioma of other bodily locations,
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Figure 2: (a) IMRT radiation treatment plan and dose-volume histogram: clinical target volume (CTV) (red line): 95% of the dose going to
100% of the volume; planning target volume (PTV) (purple line): 95% of the dose going to 95% of the volume; heart (peach-colored line):
mean heart dose of 17.2 Gy; lung (blue line): V20 = 5% and V5 = 75%. (b) Dose-volume histogram.
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Figure 3: Follow-up magnetic resonance imaging demonstrated
decreased size of the lesion posttreatment measuring 3:98 × 10:1 cm.

radiation therapy has been reported to be eﬀective in providing tumor shrinkage and pain relief in 13 cases. Doses
greater than 25 or 30 Gy resulted in higher complete
response with no long-term morbidity [11]. Alternatively,
radiotherapy on vertebral hemangiomas has a great role in
alleviating the symptoms of vertebral hemangiomas without
compromising the quality of life [12, 13]. However, there is
little information regarding radiation eﬀectiveness and
dose-response data in cardiac hemangioma. To be the best
of our knowledge, this is the ﬁrst report of a cardiac cavernous hemangioma treated with radiotherapy alone and having more than 10 years of follow-up. A total dose of 30 Gy
was given with complete symptom relief after treatment.
As such, it does seem reasonable that this data could be
extrapolated to include hemangiomas of other bodily locations. Radiotherapy provided complete long-term (10 years)
symptom relief which was clinically evident after the treatment as seen in our patient with a dose greater than 25 Gy.
IMRT used in our patient is a feasible option in cardiac
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Figure 4: Follow-up magnetic resonance imaging demonstrated
decreased size of the lesion posttreatment measuring 2:96 × 7:17 cm.

hemangiomas given its superior dose distribution and significant sparing of dosage to surrounding OARs. Recent
advances in image-guided radiation therapy such as hybrid
MR-linear accelerators may allow more eﬃcient real-time
tracking of the target and more eﬃcacious sparing of OARs
in benign conditions [2].

4. Conclusion
Surgically unresectable cardiac hemangiomas can be treated
with radiation therapy alone with a dose of 30 Gy for symptomatic relief; however, further studies are needed to support our ﬁndings. Clinical symptoms and pericardial
eﬀusion both resolved in this case, and reduction in tumor
size was also witnessed. As such, long-term outcomes seem
successful and satisfactory.
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